Bausch + Lomb ($BLCO) Stock Forecast: Up 5.5% Today

What is Bausch + Lomb?

Bausch + Lomb (BLCO) is a leading vision care company that focuses on innovation and investments in its product pipeline. The company has shown strong growth across its Vision Care, Surgical, and Pharmaceuticals segments.

Why is Bausch + Lomb going up?

BLCO stock is up 5.5% on Feb 19, 2026 16:21

• BLCO stock experienced a strong bullish movement, hitting a 52-week high at $17.87.
• The bullish trend can be attributed to the company's robust financial results for Q4 and full-year 2025, with significant revenue growth in key segments.
• Analysts' positive outlook on BLCO's profitability for the year, despite concerns about overvaluation, has likely contributed to investor confidence and the stock's upward momentum.
• The company's emphasis on strategic initiatives like MIEBO sales and R&D pipeline development, as well as its commitment to financial excellence, has further bolstered investor sentiment and contributed to the bullish market movement.

BLCO Price Chart

BLCO Technical Analysis

BLCO News

Bausch & Lomb Looks for Long-Term Growth Fueled by Innovation and Pipeline Investments

Bausch & Lomb, a major vision care company, is seeking long-term growth through continued innovation and investments in its product pipeline. The company, which spun off from Bausch Health in 2022, operates across vision care, surgical, and ophthalmic pharmaceuticals segments. Analyst Keonhee Kim highlights strong results driven by growth momentum, solid execution, and strategic pipeline investments.

https://www.morningstar.com/company-reports/1432063-bausch-lomb-looks-for-long-term-growth-fueled-by-innovation-and-pipeline-investments

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

Bausch + Lomb announced its fourth-quarter and full-year 2025 financial results, with fourth-quarter revenue reaching $1.405 billion and full-year revenue at $5.101 billion, showing growth of 10% and 6% respectively. The company delivered meaningful EBITDA margin expansion and provided 2026 guidance, projecting full-year revenue between $5.375 billion and $5.475 billion. Key drivers included strong performance in Vision Care, Surgical, and Pharmaceuticals segments, with significant sales of MIEBO® and growth in contact lenses.

https://aijourn.com/bausch-lomb-announces-fourth-quarter-and-full-year-2025-results-provides-2026-guidance/

Bausch + Lomb Q4 and Full-Year 2025 Financial Results

Bausch + Lomb (BLCO) announced its financial results for Q4 and full-year 2025, reporting significant revenue growth driven by its Vision Care, Surgical, and Pharmaceuticals segments. The company provided optimistic guidance for 2026, projecting increased revenue and adjusted EBITDA, and highlighted progress in strategic initiatives like MIEBO sales and R&D pipeline development. CEO Brent Saunders emphasized the company's commitment to financial excellence and its three-year plan.

https://www.tradingview.com/news/tradingview:4314184f3f02b:0-bausch-lomb-q4-and-full-year-2025-financial-results/

Bausch + Lomb stock hits 52-week high at $17.87 By Investing.com

Bausch + Lomb Corp (BLCO) stock reached a 52-week high of $17.87, reflecting a 17.04% gain over the past six months, despite analyst views of the company being overvalued. The company is set to report earnings, and analysts predict profitability this year due to revenue growth and positive EBITDA, despite its $4.95 billion debt burden. RBC Capital and Stifel have adjusted price targets, with RBC maintaining an Outperform rating and Stifel keeping a Hold rating due to competitive concerns.

https://in.investing.com/news/company-news/bausch--lomb-stock-hits-52week-high-at-1787-93CH-5243635

Bausch + Lomb stock hits 52-week high at $17.87

Bausch + Lomb (BLCO) stock reached a new 52-week high of $17.87, demonstrating a 17.04% gain over six months, despite being considered overvalued by InvestingPro data. Analysts predict profitability for the company this year, with RBC Capital raising its price target to $21 and Stifel maintaining a Hold rating with a revised price target of $15, reflecting ongoing evaluations of the company's performance and market position.

https://www.investing.com/news/company-news/bausch--lomb-stock-hits-52week-high-at-1787-93CH-4509625

Trending Today

MicroVision Inc. ($MVIS) Stock Forecast: Down 5.7% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Down 5.2% Today

Prime Medicine ($PRME) Stock Forecast: Down 7.8% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 6.1% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.2% Today

Jetblue Airways Corporation ($JBLU) Stock Forecast: Down 8.3% Today

Plug Power Inc. ($PLUG) Stock Forecast: Down 5.5% Today

Marathon Digital Holdings Inc. ($MARA) Stock Forecast: Down 6.7% Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Down 8.0% Today

Stryker Corporation ($SYK) Stock Forecast: Down 1.9% Today

Bausch + Lomb Price History

30.06.2025 - BLCO Stock was down 6.3%

• Despite surpassing earnings and revenue estimates in Q2, BLCO experienced a bearish movement.
• The market may have reacted negatively due to profit-taking by investors after a period of strong performance.
• Investors might be concerned about future growth prospects despite the positive Q2 results, leading to a sell-off in the stock.
• It's possible that external factors such as overall market conditions or sector-specific news influenced the bearish movement in BLCO's stock price.

20.09.2025 - BLCO Stock was up 5.1%

• The bullish movement in BLCO's stock could be attributed to the news of activist investor Jana Partners seeking a strategic overhaul at Cooper Companies and suggesting a potential merger between Cooper's contact lens division and Bausch + Lomb.
• Investors might view this potential merger as a positive strategic move that could enhance Bausch + Lomb's market position and drive future growth.
• The market's positive reaction indicates confidence in the potential synergies and benefits that could arise from the merger, leading to increased investor optimism and driving up BLCO's stock price.

24.03.2025 - BLCO Stock was up 5.1%

• BLCO's stock showed significant bullish movement today.
• Comparisons with DHR may have triggered investor interest and confidence in BLCO's value proposition.
• Despite concerns of a possible decline in earnings, which may have already been factored in by the market, it led to a positive surprise and boosted the stock's performance.
• Investors seem to be focusing on BLCO's long-term growth potential over short-term earnings worries, fueling the bullish momentum.

13.00.2026 - BLCO Stock was down 1.4%

• Despite an increase in the target price by a prominent financial institution, BLCO.US witnessed a downtrend in its stock price during the trading session.
• Market sentiment could have been impacted by the repeated "Hold" recommendation from the same financial institution, highlighting a scarcity of strong buy endorsements.
• Concerns among investors regarding the future trajectory of the stock may have triggered profit-taking activities, contributing to the bearish movement.
• Various external factors or overall market conditions might have played a role in the stock's decline, potentially overshadowing the positive target price adjustment by the financial institution.

29.06.2025 - BLCO Stock was up 2.6%

• The market reacted positively to analysts estimating a decline in earnings for BLCO.
• Investors might be anticipating that the company's performance will exceed these lowered expectations.
• This unexpected optimism could have led to increased buying activity, driving the stock price higher.
• It will be interesting to see if BLCO can defy the projections and surprise the market with its earnings report.

19.01.2026 - BLCO Stock was up 5.5%

• BLCO stock experienced a strong bullish movement, hitting a 52-week high at $17.87.
• The bullish trend can be attributed to the company's robust financial results for Q4 and full-year 2025, with significant revenue growth in key segments.
• Analysts' positive outlook on BLCO's profitability for the year, despite concerns about overvaluation, has likely contributed to investor confidence and the stock's upward momentum.
• The company's emphasis on strategic initiatives like MIEBO sales and R&D pipeline development, as well as its commitment to financial excellence, has further bolstered investor sentiment and contributed to the bullish market movement.

10.03.2025 - BLCO Stock was down 5.0%

• Despite a 13.9% increase in the previous session, the stock experienced a substantial bearish movement, potentially signaling a trend reversal.
• Investor sentiment may have been influenced by recent changes in earnings estimates, prompting profit-taking and a notable sell-off.
• The absence of consistent momentum in the short term likely played a role in the stock's decline as investors reviewed their BLCO positions.
• The cautious behavior of market participants regarding the stock's future performance appears to have led to the bearish movement observed today.

17.01.2026 - BLCO Stock was up 5.0%

• BLCO experienced a strong bullish movement as investors recognize its steady growth potential and essential healthcare offerings.
• Positive outlook on BLCO's stability and real-world utility likely contributed to increased investor interest and buying pressure.
• Investors seeking a defensive play amidst high-volatility stocks may have turned to BLCO for its reliable performance and brand recognition in the eye-care market.

30.03.2025 - BLCO Stock was down 20.4%

• BLCO experienced a strong bearish movement today.
• The pre-market session showed big stocks like Eagle Financial Services falling sharply, indicating a broader negative sentiment in the market.
• The comparison between BLCO and DHR in terms of value might have influenced investor decisions, potentially leading to a sell-off of BLCO shares.
• Analysts estimating a decline in BLCO's earnings could have further contributed to the bearish movement as investors adjusted their positions based on these expectations.

19.01.2025 - BLCO Stock was up 0.0%

• BLCO stock saw significant upward movement today.
• The company exceeded both earnings and revenue projections for the fourth quarter of 2024, indicating robust financial performance.
• The market responded favorably to the outperformance, reflecting confidence in BLCO's growth potential.
• The positive market sentiment towards BLCO is likely influenced by its strong financial results and growth opportunities.

30.03.2025 - BLCO Stock was down 14.7%

• BLCO reported a significant loss in Q1 and missed revenue estimates, leading to a bearish movement in the stock.
• The negative earnings surprise of -333.33% and slight revenue miss of 0.86% likely contributed to investor concerns and selling pressure.
• The broader market sentiment, with U.S. stock futures slightly lower and other big stocks like Eagle Financial Services also moving lower, added to the downward pressure on BLCO.
• Investors may be cautious about the company's future performance based on the disappointing financial results, prompting them to sell off their positions in BLCO.

11.11.2025 - BLCO Stock was up 5.3%

• An analyst's "Hold" rating possibly raised initial investor uncertainty.
• The market, however, appears to perceive this rating positively, indicating stability and confidence in the company.
• This sentiment reflects a perceived steady trajectory for Bausch + Lomb Corp., driving heightened investor interest and a bullish stock price movement today.